HDL-cholesterol and prediction of coronary heart disease: Modified by physical fitness?. A 28-year follow-up of apparently healthy men

Atherosclerosis

Volumn 220, Issue 1, 2012, Pages 250-256

  Skretteberg, Per Torger ^a   Grundvold, Irene ^a   Kjeldsen, Sverre E ^a,b   Erikssen, Jan E ^b   Sandvik, Leiv ^a,b   Liestøl, Knut ^c   Erikssen, Gunnar ^d   Pedersen, Terje R ^a,b   Bodegard, Johan ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cardiovascular disease; Epidemiology; Exercise; HDL; Physical fitness; Prediction

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; FITNESS; FOLLOW UP; HEALTH SURVEY; HEART DEATH; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SMOKING; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CORONARY DISEASE; EXERCISE TEST; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NORWAY; PHYSICAL FITNESS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRIGLYCERIDES;

EID: 84155172101     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.10.009     Document Type: Article

References (32)

1. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
2. Assmann G., Schulte H., Von Eckardstein A., Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The procam experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124(Suppl.):S11-S20.
3. Stensvold I., Urdal P., Thurmer H., Tverdal A., Lund-Larsen P.G., Foss O.P. High-density lipoprotein cholesterol and coronary, cardiovascular and all cause mortality among middle-aged Norwegian men and women. Eur Heart J 1992, 13:1155-1163.
4. Marrugat J., Elosua R., Covas M.I., Molina L., Rubies-Prat J. Amount and intensity of physical activity, physical fitness, and serum lipids in men. The marathom investigators. Am J Epidemiol 1996, 143:562-569.
5. Baruth M., Wilcox S., Sallis J.F., King A.C., Marcus B.H., Blair S.N. Changes in CVD risk factors in the activity counseling trial. Int J Gen Med 2011, 4:53-62.
6. Kodama S., Tanaka S., Saito K., et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 2007, 167:999-1008.
7. Lakka T.A., Salonen J.T. Physical activity and serum lipids: a cross-sectional population study in eastern Finnish men. Am J Epidemiol 1992, 136:806-818.
8. Leon A.S., Sanchez O.A. Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc 2001, 33:S502-S515. [discussion S28-9].
9. Tambalis K., Panagiotakos D.B., Kavouras S.A., Sidossis L.S. Responses of blood lipids to aerobic, resistance, and combined aerobic with resistance exercise training: a systematic review of current evidence. Angiology 2009, 60:614-632.
10. Erikssen G., Liestol K., Bjornholt J., Thaulow E., Sandvik L., Erikssen J. Changes in physical fitness and changes in mortality. Lancet 1998, 352:759-762.
11. Sandvik L., Erikssen J., Thaulow E., Erikssen G., Mundal R., Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med 1993, 328:533-537.
12. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
13. Mineo C., Deguchi H., Griffin J.H., Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ Res 2006, 98:1352-1364.
14. Wannamethee S.G., Lowe G.D., Whincup P.H., Rumley A., Walker M., Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002, 105:1785-1790.
15. Olchawa B., Kingwell B.A., Hoang A., et al. Physical fitness and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2004, 24:1087-1091.
16. Kraus W.E., Houmard J.A., Duscha B.D., et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002, 347:1483-1492.
17. Erikssen J., Enge I., Forfang K., Storstein O. False positive diagnostic tests and coronary angiographic findings in 105 presumably healthy males. Circulation 1976, 54:371-376.
18. Burstein M.S.H.R., Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970, 11:583-595.
19. Stein E.A., Steiner P.M., Gartside P.S., Glueck C.J. Development and evaluation of a method for quantitation of plasma high-density-lipoprotein cholesterol. Clin Chem 1978, 24:1112-1115.
20. Wannamethee S.G., Whincup P.H., Shaper A.G., Rumley A., Lennon L., Lowe G.D. Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men. J Thromb Haemost 2009, 7:1605-1611.
21. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298:776-785.
22. Lewington S., Whitlock G., Clarke R., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839.
23. Cooney M.T., Dudina A., De Bacquer D., et al. How much does HDL cholesterol add to risk estimation? A report from the score investigators. Eur J Cardiovasc Prev Rehabil 2009, 16:304-314.
24. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008, 359:2195-2207.
25. Van Der Steeg W.A., Holme I., Boekholdt S.M., et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein a-i: significance for cardiovascular risk: the ideal and epic-norfolk studies. J Am Coll Cardiol 2008, 51:634-642.
26. Bonjer F.H. Measurement of working capacity by assessment of the aerobic capacity in a single session. Fed Proc 1966, 25:1363-1365.
27. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med 1999, 341:410-418.
28. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., Grace K.A. Arterial biology for the investigation of the treatment effects of reducing cholesterol (arbiter) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512-3517.
29. Waksman R., Torguson R., Kent K.M., et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010, 55:2727-2735.
30. Fayad Z.A., Mani V., Woodward M., et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-plaque): a randomised clinical trial. Lancet 2011, (September (9)). [Epub ahead of print]. 10.1016/S0140-6736(11)61383-4.
31. Goldberg I.J., Mosca L., Piano M.R., Fisher E.A. Aha science advisory: wine and your heart: a science advisory for healthcare professionals from the nutrition committee, council on epidemiology and prevention, and council on cardiovascular nursing of the American heart association. Circulation 2001, 103:472-475.
32. Williams P.T. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med 1996, 334:1298-1303.